Back to news

Praxis Precision Medicines jumps after Q3 update keeps dual FDA catalysts in focus

Investivoq PriceTracker

Praxis Precision Medicines (PRAX) is up 19.9% today. Here is some analysis on what might have caused this price movement.

Analysis: The rally appears tied to Praxis’ third-quarter update, which kept two near-term FDA review catalysts in place and highlighted a cash runway into 2028. Investors also seemed encouraged by signs of commercial launch readiness and by a quarterly loss that screened better than consensus expectations.

Details:

  • Praxis said both flagship programs remain under FDA review, with a December 27, 2026 action date for relutrigine and a January 29, 2027 action date for ulixacaltamide.
  • The company said it had about $1.3 billion in cash, cash equivalents and marketable securities as of September 30, 2026, which it expects will fund operations into 2028.
  • Management said launch preparations are advancing, including a fully hired relutrigine commercial team and ulixacaltamide sales-force hiring expected to be completed in the fourth quarter of 2026.
  • The quarter’s net loss was $3.23 per share, and market data services flagged the result as an earnings beat versus analyst expectations.

    • Sources:

    Praxis Precision Medicines, SEC, Google Finance

    Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

    $PRAX Insider Trading Activity

    PRAX Insider Trades

    $PRAX insiders have traded $PRAX stock on the open market 12 times in the past 6 months. Of those trades, 0 have been purchases and 12 have been sales.

    Here’s a breakdown of recent trading of $PRAX stock by insiders over the last 6 months:

    • JILL DESIMONE has made 0 purchases and 12 sales selling 11,600 shares for an estimated $3,611,334.

    To track insider transactions, check out Investivoq's insider trading dashboard. You can access data on insider stock transactions through the Investivoq API insider transaction endpoint.

    EARLY ACCESS
    Receive PRAX Data Alerts
    Real-time alerts on filings, insider trades, and market signals — before everyone else.
    Get Alerts →

    $PRAX Hedge Fund Activity

    We have seen 210 institutional investors add shares of $PRAX stock to their portfolio, and 117 decrease their positions in their most recent quarter.

    Here are some of the largest recent moves:

    • ORBIS ALLAN GRAY LTD removed 942,692 shares (-38.1%) from their portfolio in Q2 2026, for an estimated $315,603,854
    • INVESCO LTD. added 476,151 shares (+775.5%) to their portfolio in Q2 2026, for an estimated $159,410,593
    • RA CAPITAL MANAGEMENT, L.P. removed 373,787 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $125,140,149
    • NORGES BANK added 342,615 shares (+7869.0%) to their portfolio in Q2 2026, for an estimated $114,704,075
    • PRICE T ROWE ASSOCIATES INC /MD/ added 312,147 shares (+49.5%) to their portfolio in Q2 2026, for an estimated $104,503,694
    • POLAR CAPITAL HOLDINGS PLC added 279,131 shares (+inf%) to their portfolio in Q2 2026, for an estimated $93,450,267
    • CORMORANT ASSET MANAGEMENT, LP removed 245,500 shares (-27.7%) from their portfolio in Q2 2026, for an estimated $82,190,945

    To track hedge funds' stock portfolios, check out Investivoq's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Investivoq API 13F endpoint.

    $PRAX Congressional Stock Trading

    Members of Congress have traded $PRAX stock 2 times in the past 6 months. Of those trades, 2 have been purchases and 0 have been sales.

    Here’s a breakdown of recent trading of $PRAX stock by members of Congress over the last 6 months:

    • REPRESENTATIVE GILBERT RAY CISNEROS, JR. has traded it 2 times. They made 2 purchases worth up to $30,000 on 09/29, 07/30 and 0 sales.

    To track congressional stock trading, check out Investivoq's congressional trading dashboard. You can access data on congressional stock trades through the Investivoq API Congress trades endpoint.

    $PRAX Analyst Ratings

    Wall Street analysts have issued reports on $PRAX in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

    Here are some recent analyst ratings:

    • BTIG issued a "Buy" rating on 06/02/2026

    To track analyst ratings and price targets for $PRAX, check out Investivoq's $PRAX forecast page.

    $PRAX Price Targets

    Multiple analysts have issued price targets for $PRAX recently. We have seen 9 analysts offer price targets for $PRAX in the last 6 months, with a median target of $575.0.

    Here are some recent targets:

    • Ami Fadia from Needham set a target price of $575.0 on 06/29/2026
    • Leonid Timashev from RBC Capital set a target price of $449.0 on 06/18/2026
    • Kambiz Yazdi from BTIG set a target price of $810.0 on 06/02/2026
    • Douglas Tsao from HC Wainwright & Co. set a target price of $1201.0 on 06/02/2026
    • David Hoang from Deutsche Bank set a target price of $374.0 on 06/02/2026
    • Laura Chico from Wedbush set a target price of $162.0 on 06/02/2026
    • Joel Beatty from Baird set a target price of $400.0 on 06/02/2026

    This article is not financial advice. See Investivoq's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.